Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Merck
Colorcon
Harvard Business School
Medtronic

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Onartuzumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Onartuzumab: Patents, clinical trial progress, indications

Onartuzumab is an investigational drug.

There have been 15 clinical trials for Onartuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Stomach Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and M.D. Anderson Cancer Center.

There are thirteen US patents protecting this investigational drug and four hundred and fifty-one international patents.

Recent Clinical Trials for Onartuzumab
TitleSponsorPhase
An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored StudyHoffmann-La RochePhase 3
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)Genentech, Inc.Phase 1/Phase 2
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)M.D. Anderson Cancer CenterPhase 1/Phase 2

See all Onartuzumab clinical trials

Clinical Trial Summary for Onartuzumab

Top disease conditions for Onartuzumab
Top clinical trial sponsors for Onartuzumab

See all Onartuzumab clinical trials

US Patents for Onartuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Onartuzumab   See Pricing Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   See Pricing
Onartuzumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Onartuzumab   See Pricing Cancer treatment with c-met antagonists and correlation of the latter with HGF expression Genentech, Inc. (South San Francisco, CA)   See Pricing
Onartuzumab   See Pricing Methods of treating glioblastoma multiforme using ibudilast MediciNova, Inc. (La Jolla, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Onartuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Onartuzumab Canada 2900764 2033-02-08   See Pricing
Onartuzumab European Patent Office 2954056 2033-02-08   See Pricing
Onartuzumab Hong Kong 1218930 2033-02-08   See Pricing
Onartuzumab Japan 2016509014 2033-02-08   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Medtronic
McKesson
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.